STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Innoviva, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Innoviva, Inc. (INVA) reported insider equity activity for its Chief Financial Officer, Stephen Basso, on a Form 4. On November 15, 2025, he acquired 604 shares of common stock at $0 under the Innoviva Employee Stock Purchase Plan. On November 20, 2025, 237 shares of common stock were withheld by Innoviva at $21.16 per share to cover income tax obligations tied to the quarterly vesting of previously granted equity awards. After these transactions, he directly owned 51,257 shares of Innoviva common stock.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Basso Stephen

(Last) (First) (Middle)
1350 OLD BAYSHORE HIGHWAY, SUITE 400

(Street)
BURLINGAME CA 94010

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Innoviva, Inc. [ INVA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/15/2025 A 604(1) A $0 51,494 D
Common Stock 11/20/2025 F 237(2) D $21.16 51,257 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes 604 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on November 15, 2025.
2. The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
/s/ Stephen Basso 11/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Innoviva (INVA) report on this Form 4?

The Form 4 shows the CFO acquired 604 shares of Innoviva common stock under the Employee Stock Purchase Plan and had 237 shares withheld to pay taxes on vested equity.

Who is the reporting person in this Innoviva (INVA) Form 4 filing?

The reporting person is Stephen Basso, who serves as Chief Financial Officer of Innoviva, Inc.

How many Innoviva (INVA) shares does the CFO own after these transactions?

Following the reported transactions, the CFO directly owned 51,257 shares of Innoviva common stock.

What was the purpose of the 604 Innoviva (INVA) shares acquired?

The 604 shares were acquired on November 15, 2025 under the Innoviva, Inc. Employee Stock Purchase Plan.

Why were 237 Innoviva (INVA) shares disposed of in this Form 4?

The 237 shares were withheld by Innoviva at $21.16 per share to satisfy income tax withholding obligations related to the quarterly vesting of previously granted equity awards.

Are the Innoviva (INVA) shares held directly or indirectly by the CFO?

The Form 4 indicates the 51,257 shares of Innoviva common stock are held with direct (D) ownership.

Innoviva

NASDAQ:INVA

INVA Rankings

INVA Latest News

INVA Latest SEC Filings

INVA Stock Data

1.62B
73.97M
0.98%
122.14%
10.67%
Biotechnology
Pharmaceutical Preparations
Link
United States
BURLINGAME